BeOne Medicines Ltd. SEC Filings

BeOne Medicines (ONC) filed a routine Form 4 showing CEO/Director John Oyler’s mandatory tax-withholding sale of 3,174 American Depositary Shares (≈41,262 ordinary shares) on 06/23/2025 at an average price of about $262, totaling roughly $0.83 million.

Post-sale, Oyler still controls ≈54.2 million ordinary shares through direct and indirect holdings, so his ownership percentage is effectively unchanged. No other transactions or material changes were disclosed.

BeOne Medicines Ltd. has filed a Form 144 notice for the proposed sale of 2,007 American Depositary Shares (ADS) through Morgan Stanley Smith Barney LLC. The shares have an aggregate market value of $516,822.57 and are planned to be sold on the NASDAQ around June 24, 2025.

The securities were originally acquired as Restricted Stock Units from the issuer on June 15, 2025. The filing also discloses significant recent trading activity by XIAODONG WANG through a 10b5-1 trading plan, including:

• June 10, 2025: 41,760 ADS sold for $10,975,317.26
• May 13, 2025: 41,760 ADS sold for $9,333,272.30
• April 14, 2025: 41,760 ADS sold for $10,133,594.35

The total outstanding shares of the company are 56,964,739. This Form 144 represents the declaration of intention to sell securities acquired through RSUs, following a pattern of systematic sales through an established 10b5-1 trading plan.

BeOne Medicines Ltd. (symbol: ONC) filed a Form 144 indicating a planned disposition of American Depositary Shares (ADSs) by shareholder Lai Wang.

• Securities to be sold: 1,028 ADSs
• Aggregate market value: US $267,280
• Approximate sale date: 23 June 2025
• Exchange: NASDAQ
• Total ADSs outstanding: 109,600,154 (proposed sale equals ≈0.0009 %)

The filing also discloses that the same shareholder sold 3,049 ADSs during the prior three-month period, generating gross proceeds of US $785,552.36 across three transactions dated 6 June, 16 June, and 17 June 2025.

The shares to be sold were acquired through restricted-stock vesting under a registered plan on 22 June 2025; full payment was made in stock ("Not Applicable" cash consideration). Morgan Stanley Smith Barney LLC is listed as the executing broker.

The company’s Rule 144 notice states that the seller attests to having no undisclosed material adverse information about the issuer at the time of filing.

Investor takeaway: The proposed sale represents a very small fraction of total shares outstanding. While repeated sales may signal individual liquidity preferences, the size is unlikely to be financially material to BeOne Medicines’ float or trading dynamics.

BeOne Medicines Ltd. (Ticker: ONC) filed a Form 144 announcing a proposed sale of American Depositary Shares (ADS). The notice covers 1,363 ADS valued at $354,380, to be brokered by Morgan Stanley Smith Barney LLC on the NASDAQ around 23 June 2025. With 109,600,154 ADS outstanding, the transaction represents only about 0.0012 % of total shares, suggesting negligible dilution and limited supply pressure.

The seller, Xiaobin Wu (Grand Cayman), obtained the shares through restricted-stock vesting on 22 June 2025 under a registered plan; therefore no cash outlay was required. The filer attests to possessing no undisclosed material adverse information about the company at the time of filing.

Recent insider activity is noteworthy: during the past three months the same individual sold 56,028 ADS across four trades (04 Apr–17 Jun 2025) for total gross proceeds of roughly $15.7 million. The current filing continues that trend, albeit at a far smaller scale than the single 51,921-share sale recorded on 01 Apr 2025.

Investor considerations

• Form 144 is a disclosure of intent; execution is not guaranteed.
• The share count is immaterial relative to float, limiting near-term market impact.
• Continued insider selling may influence sentiment and is worth monitoring for potential signals about insider confidence.

Form 4 overview: On 18 Jun 2025, BeOne Medicines Ltd. (ticker ONC) reported a change in ownership by Senior Vice-President & General Counsel Henry Chan Lee.

• Transaction date: 16 Jun 2025
• Security sold: 422 American Depositary Shares (ADS)
• Price: US $266.50 per ADS
• Underlying shares: Each ADS represents 13 ordinary shares; sale equals 5,486 ordinary shares
• Reason: Mandatory tax-withholding sale linked to the vesting of a restricted share-unit (RSU) grant that began vesting 15 Jun 2023 (25 % annually)
• Post-sale holdings: 278,434 ordinary shares held directly; 0 ADS

No derivative transactions or additional disposals were reported. The filing indicates that unvested RSUs may accelerate under certain termination scenarios, but no acceleration occurred in this report.

Investor takeaway: The disposition is small relative to the executive’s remaining equity stake (≈2% of total direct holdings based on ADS equivalence) and was executed solely to satisfy tax obligations. No strategic signal or company-level financial data accompanies this filing.

Form 4 filing overview: BeOne Medicines Ltd. (ticker ONC) President & COO Xiaobin Wu reported three sales of the company’s American Depositary Shares (ADS) on 16-17 Jun 2025. Each ADS represents 13 ordinary shares.

• Shares sold: 2,173 ADS in total (1,443 ADS at $265.4695 weighted average, 100 ADS at $266.22, and 630 ADS at $250.8686).
• Proceeds: ≈ $555 thousand based on the disclosed prices.
• Reason: All sales were automatically executed under the mandatory tax-withholding feature of the executive’s Restricted Share Unit (RSU) agreements, coinciding with scheduled vesting dates.
• Residual ownership: After the transactions Wu still directly owns 1,246,047 ordinary shares and 0 ADS; indirectly, his spouse controls 4,000 ADS.
• Vesting schedule: The underlying RSUs vest 25 % annually from either 15 Jun 2023 or 16 Jun 2021, with accelerated vesting on certain termination events.

Investor take-away: The disposition represents <1 % of the executive’s economic exposure to ONC and was not discretionary trading. Accordingly, the filing is viewed as routine compliance rather than a signal of changing insider sentiment.

Form 4 Overview – BeOne Medicines Ltd. (ONC)

Chief Executive Officer and Director John Oyler filed a Form 4 covering two transactions executed on 16-17 June 2025. Both involved the company’s American Depositary Shares (ADS), each representing 13 ordinary shares.

• 16 Jun 2025: 3,680 ADS sold under transaction code “S” at a weighted-average price of $266.0452.
• 17 Jun 2025: 1,460 ADS sold under transaction code “S” at a weighted-average price of $256.4885.

Total ADS disposed: 5,140, equivalent to ≈66,820 ordinary shares. Gross proceeds, based on the reported weighted averages, amount to roughly $1.35 million.

The filing notes that both sales were automatically executed to cover mandatory tax-withholding obligations tied to the vesting of previously granted restricted share units (RSUs). They were not discretionary open-market sales.

Post-transaction holdings

• Direct holdings: 8,215,021 ordinary shares and 0 ADS.
• Indirect holdings (multiple trusts and entities): approximately 46 million ordinary shares, as detailed in five footnoted ownership vehicles. Oyler disclaims beneficial ownership of several of these positions.

No derivative security activity was reported. The transactions do not change Oyler’s board or executive status and appear administrative rather than strategic. Given the small proportion of shares sold relative to his overall beneficial ownership, market impact is likely limited.